Why Zura Bio Limited’s (ZURA) Stock Is Up 6.72%
As of Friday, November 06, Zura Bio Limited’s ZURA share price has surged by 6.72%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Commentary & Analysis
Why Zura Bio Limited’s (ZURA) Stock Is Down 5.40%
As of Thursday, October 29, Zura Bio Limited’s ZURA share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Tudor Pop
Why Zura Bio Limited’s (ZURA) Stock Is Up 7.14%
As of Wednesday, October 28, Zura Bio Limited’s ZURA share price has surged by 7.14%, which has investors questioning if this is right time to sell.Michael Rose
Why Zura Bio Limited’s (ZURA) Stock Is Up 9.97%
As of Tuesday, October 27, Zura Bio Limited’s ZURA share price has surged by 9.97%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Zura Bio Limited’s (ZURA) Stock Is Up 5.65%
As of Monday, October 26, Zura Bio Limited’s ZURA share price has surged by 5.65%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $358.3 | $214.3 | 35% |
|
| Shares Out (Mil) | 127.7 | 53.9 | 67% |
|
| Institutional Ownership | 83.8% | 92.9% | 52% |
|
| Float (Mil) | 45.6 | 41.4 | 45% |
|
| Beta | 0.01 | 0.96 | 6% |
|
| Avg Daily Volume (000s) | 3,729 | 506 | 88% |
|
| Price Change (52-week) |
7.8% | 43.9% | 57% |
|
| Growth | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.186) | ($0.786) | ($0.678) | |
| Month Ago EPS | ($0.190) | ($0.800) | ($0.690) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.170) | ($0.753) | ($0.643) | |
| Year/Year Chg | (7.9%) | (25.5%) | (18.5%) | |
| Financials | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($94) | ($44) | 11% |
|
| EPS (TTM) | ($1.059) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $49 | $1 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $231 | $172 | 27% |
|
| Valuation | ZURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.02 | 2.00 | 56% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (55.2%) | (47.5%) | 11% |
|
| ROE | (65.4%) | (53.3%) | 13% |
|
| Liabilities to Assets | 8.7% | 29.6% | 5% |
|
| F-Score | 2 | 2 | 7% |
|
Zura Bio Limited did not pass any screens on 11/5/2026.
